---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-25-000055"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:55:09.456169+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Exagen appoints former Silk Road Medical CEO Chas McKhann to Board

## Summary
- Chas McKhann appointed Class III director effective July 17, 2025; term expiring at 2028 annual meeting.
- Previously served as President/CEO of Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific.
- Board size increased from 7 to 8 members; McKhann also joins Compensation and Nominating Committees.
- McKhann received 7,500 RSUs vesting over 4 years; annual option for 9,000 shares under amended compensation plan.
- Board approved amended non-employee director compensation program effective July 17, 2025.

## SEC filing metadata
- accession: 0001274737-25-000055
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473725000055/0001274737-25-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473725000055/exdx-20250717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-25-000055
- JSON: https://secwatch.observer/filing/0001274737-25-000055.json
- Plain text: https://secwatch.observer/filing/0001274737-25-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.